Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 483 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: beta-lactam Clear all
Terminated Phase 2 Interventional Results available

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

NCT05753735
View directory record Official record
Conditions
Pancreatic Fistula
Interventions
Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

NCT00835549
View directory record Official record
Conditions
Healthy
Interventions
Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 3, 2026, 5:32 AM EDT
Completed No phase listed Observational

Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study

NCT02179710
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adherence dashboard motivational interviewing
Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Sep 3, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Microbiome and Association With Implant Infections

NCT05020574
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Genetic Predisposition to Disease
Interventions
Cephalexin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Early Phase 1 Interventional

Vancomycin and Tobramycin Powder Use in Acute Open Fractures

NCT05849090
View directory record Official record
Conditions
Infections
Interventions
Cephalosporin or clindamycin/vancomycin antibiotics.., Vancomycin and Tobramycin antibiotics.
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 3, 2026, 5:32 AM EDT
Not listed Not applicable Interventional

Does a Safety Difference Exist Between IV Push and IV Piggyback Antibiotics?

NCT03360617
View directory record Official record
Conditions
Infection
Interventions
Syringe IV Push over 2-3 minutes, Piggyback over 30 minutes
Device
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 3, 2026, 5:32 AM EDT
Recruiting Phase 4 Interventional

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

NCT03014687
View directory record Official record
Conditions
Antibiotics, Pituitary Adenoma
Interventions
Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 84 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions

NCT03578965
View directory record Official record
Conditions
Premalignant Vulvar Lesion, Benign Vulvar Lesion
Interventions
Cefazolin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT03217136
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 3, 2026, 5:32 AM EDT
Withdrawn No phase listed Observational

The Role of Antibiotic Prophylaxis in Cleft Palate and Velopharyngeal Insufficiency Repair

NCT02688634
View directory record Official record
Conditions
Cleft Palate
Interventions
Amoxicillin
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Month to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tumescent Antibiotic Delivery Pharmacokinetics

NCT01046981
View directory record Official record
Conditions
Prevention of Surgical Site Infections
Interventions
Tumescent Antibiotic Delivery of cefazolin with or without metronidazole, Intravenous Antibiotic Delivery
Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
21 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Sep 3, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

NCT06303128
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Amoxicillin 250 MG, Placebo, Amoxicillin 62.5mg, Amoxicillin 187.5mg
Drug
Lead sponsor
James Tarbox, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Skin Testing Reagents for Penicillin Allergy

NCT01818336
View directory record Official record
Conditions
History of IgE Dependent Reaction to a Penicillin Product
Interventions
Penicillin skin test kit
Drug
Lead sponsor
AllerQuest LLC
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

NCT00492973
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic; Arthrosis
Interventions
methylprednisolone acetate, active comparator
Drug
Lead sponsor
New Lexington Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 3, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06733675
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
View directory record Official record
Conditions
Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
Interventions
cefixime, irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

NCT06547554
View directory record Official record
Conditions
Bacterial Infections
Interventions
Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

NCT01844856
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
Eravacycline, Ertapenem, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Florence, Alabama • Mobile, Alabama • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

NCT00894439
View directory record Official record
Conditions
Healthy Subjects
Interventions
BLI-489/Piperacillin, BLI-489, Piperacillin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2009 · Synced Sep 3, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

Clavulanic Acid for the Treatment of Cocaine Use Disorder

NCT05562349
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Clavulanic Acid Only Product, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 3, 2026, 5:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Asymptomatic Bacteriuria in Pregnancy

NCT02911662
View directory record Official record
Conditions
Bacteriuria (Asymptomatic) in Pregnancy
Interventions
Cephalexin, Nitrofurantoin
Drug
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 3, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562
View directory record Official record
Conditions
Infections, Intestinal
Interventions
Drug: GSK2251052, Meropenem, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

NCT02709382
View directory record Official record
Conditions
Renal Impairment
Interventions
Cefepime and Tazobactam combination
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 3, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 3, 2026, 5:32 AM EDT